Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1147877

registered interest
date	02/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Homes: Abuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the 67,500 allegations of mistreatment in care homes received by the Care Quality Commission in 2018, what steps the Government will take to increase prosecution rates.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	293437
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>The Department expects those providing the service, local authorities and the Care Quality Commission (CQC) to take swift action where anyone alleges poor care, neglect or abuse.</p><p>Since 2015, the CQC has had prosecution powers pursuant to the Health and Social Care Act 2008. These include the criminal offence in respect of Regulation 12 (safe care and treatment) of the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 in cases involving avoidable harm or a significant risk of avoidable harm to service users.</p><p>Although there were 67,500 allegations of mistreatment in care homes in 2018, the number of qualified allegations will be less than this figure. Within those qualified allegations, not all of them will be of as significant concern as to begin legal proceedings in the form of criminal prosecution. As such, numbers of prosecutions will be expected to be far lower than any number of allegations.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 08/10/2019 10:54:07 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	298 label Biography information for Steve McCabe

1147926

registered interest
date	02/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Healthy Start Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the uptake of Healthy Start vouchers.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	293444
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 15:24:27 answering member 4380 label Biography information for Jo Churchill
tabling member	298 label Biography information for Steve McCabe

1147996

registered interest
date	02/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hormone Replacement Therapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps the Department has taken to ensure that women who are unable to use alternative forms of HRT have access to HRT patches.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	293445
answer	answer is ministerial correction date of answer 07/10/2019 answer text <p>The Department fully understands that maintaining access to hormone replacement therapy (HRT) medications is vitally important to many people in this country.</p><p>We are aware of ongoing supply issues with some HRT transdermal patches due to manufacturing issues. We have been working closely with all suppliers of HRT transdermal patches to maintain overall supply to patients. Although some HRT transdermal patches are affected by supply issues, supplies of other alternative HRT transdermal patches have remained available.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 07/10/2019 16:53:50 answering member 4380 label Biography information for Jo Churchill
tabling member	298 label Biography information for Steve McCabe

1146686

registered interest
date	26/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken, in light of the European Medicines Agency formally declaring that it recognises Post SSRI Sexual Dysfunction (PSSD) as a medical condition that can outlast discontinuation of SSRI and SNRI antidepressants, to provide symptomatic relief to those suffering from that condition on a long-term basis.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	291225
answer	answer is ministerial correction date of answer 01/10/2019 answer text <p>The European Medicines Agency (EMA) has not formally recognised Post SSRI Sexual Dysfunction (PSSD) as a medical condition, as it is not within the remit of the EMA to classify medical conditions.</p><p>The EMA’s Pharmacovigilance Risk Assessment Committee evaluated the available safety data on the risk of sexual disorders with selective serotonin reuptake inhibitors/serotonin norepinephrine reuptake inhibitors to establish whether the existing information about the possible side effect of sexual dysfunction fully reflected the available evidence. The review did not include an evaluation of whether PSSD is a specific medical condition.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 01/10/2019 15:34:19 answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	298 label Biography information for Steve McCabe

1135380

registered interest
date	27/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Heart Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the costs of untreated patients diagnosed with structural heart disease on the health and social care system; and how many of those patients have died while waiting for treatment in each year since 2010.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	270254
answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>The requested information is not centrally held by the Department.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 02/07/2019 16:32:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	298 label Biography information for Steve McCabe

1132765

registered interest
date	18/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	What recent discussions his Department has had with clinical commissioning groups on the Human Fertilisation and Embryology Authority’s guidance on fertility treatment.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	911423
answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>Clinical commissioning groups (CCGs) have a statutory responsibility to commission healthcare services that meet the needs of their whole population, including fertility services. The Human Fertilisation and Embryology Aauthority’s guidance for commissioners is a new tool to help them implement National Institute for Health and Care Excellence (NICE) Fertility guidelines and utilise the benchmark price for In Vitro Fertilisation.</p><p>I have written to all CCGs to promote the guidance and benchmark price, and encourage them to fully implement NICE Fertility Guideline recommendations.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/06/2019 15:21:37 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	298 label Biography information for Steve McCabe

1132403

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	265417
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265418 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	298 label Biography information for Steve McCabe

1132404

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	265418
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265417 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	298 label Biography information for Steve McCabe

1131849

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to improve NHS waiting times for cancer patients.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	263683
answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>The NHS Long Term Plan sets out plans to improve early cancer diagnosis, and a new ambition that, by 2028, the proportion of cancers diagnosed at stages one and two will rise from around half to three-quarters of cancer patients. This will be achieved through raising greater awareness of symptoms of cancer, accelerating access to diagnosis and treatment, maximising the number of cancers that are identified through screening, and harnessing new innovations in technology. A radical overhaul of the way diagnostic services are delivered will ensure that people can get their diagnosis more quickly, including the roll-out of new Rapid Diagnostic Centres across the country to upgrade and bring together the latest diagnostic equipment and expertise.</p><p> </p><p>The independent cancer taskforce recommended the introduction of a new faster diagnosis standard to ensure that people receive a life changing confirmation of whether or not they have cancer within 28 days. This proposed new standard is being considered as part of the clinical review of National Health Service access standards currently being undertaken by NHS England.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:26:47 answering member 4455 label Biography information for Seema Kennedy
tabling member	298 label Biography information for Steve McCabe

1130886

registered interest
date	10/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what comparative estimate his Department has made of the average cost of (a) caring for a dementia patient at home with care provided by family and (b) care provided in an in-patient setting.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	262230
answer	answer is ministerial correction date of answer 13/06/2019 answer text <p>The Department has made no such comparative estimate.</p><p>The average cost of caring for a dementia patient at home by family is not collected or reported centrally.</p><p>Data on the average cost of care provided in an in-patient setting is not available in the format requested.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 13/06/2019 13:33:32 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	298 label Biography information for Steve McCabe